c US partners and four international distributors to help us aggressively market and sell our novel PCT instruments and consumables. Initial orders have already been received from several of these new partners/distributors. We believe that the number of such orders will continue to increase, that products and programs planned for market release during the second half of 2012 will positively impact revenue this year, that the number of PCT applications will continue to grow, that the number of publications and presentations that cite the benefits of PCT in sample preparation will continue to expand, and that the number of research scientists introduced to the advantages of PCT will continue to increase. We further believe that the combination of these factors will result in significantly greater revenue in 2012 compared to 2011."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements i
Page: 1 2 3 4 Related biology technology :1
|SOURCE Pressure BioSciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform2
. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA3
. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment4
. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY5
. Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive6
. UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt7
. AMPAC Fine Chemicals Continues to Invest in Quality Systems8
. Profil Institute Continues to Publish New Findings in Metabolic Research9
. BiOptix continues support of Colorado-based research institutions10
. China Cord Blood Corporation Continues Share Repurchase Program11
. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition